{"id":81599,"date":"2026-05-13T13:24:12","date_gmt":"2026-05-13T13:24:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/81599\/"},"modified":"2026-05-13T13:24:12","modified_gmt":"2026-05-13T13:24:12","slug":"novo-nordisk-discloses-gifted-shares-to-cfo-associates-nvo-sec-filing","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/81599\/","title":{"rendered":"Novo Nordisk discloses gifted shares to CFO associates | NVO SEC Filing"},"content":{"rendered":"

\u00a0<\/p>\n

UNITED STATES<\/p>\n

SECURITIES AND EXCHANGE COMMISSION<\/p>\n

Washington, D.C. 20549<\/p>\n

\u00a0<\/p>\n

________________<\/p>\n

\u00a0<\/p>\n

FORM 6-K<\/p>\n

________________<\/p>\n

\u00a0<\/p>\n

REPORT OF FOREIGN PRIVATE ISSUER<\/p>\n

\u00a0<\/p>\n

Pursuant to Rule 13a-16 or 15d-16<\/p>\n

of the Securities Exchange Act of 1934<\/p>\n

\u00a0<\/p>\n

May 12,
\n2026<\/p>\n

________________<\/p>\n

\u00a0<\/p>\n

NOVO NORDISK A\/S<\/p>\n

\u00a0(Exact name
\nof Registrant as specified in its charter)<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

Novo All\u00e9 1<\/p>\n

DK- 2880, Bagsvaerd<\/p>\n

Denmark<\/p>\n

(Address of principal executive offices)<\/p>\n

________________<\/p>\n

\u00a0<\/p>\n

Indicate by check mark whether the registrant files or will file annual reports under
\ncover of Form 20-F or Form 40-F<\/p>\n

\u00a0<\/p>\n

Form 20-F \u2612\u00a0\u00a0\u00a0\u00a0\u00a0
\n \u00a0\u00a0\u00a0\u00a0\u00a0Form 40-F \u2610<\/p>\n

\u00a0\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\"\"\u00a0<\/p>\n

\"\"\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

Trading in Novo Nordisk shares by board
\nmembers, executives and associated persons<\/p>\n

\u00a0<\/p>\n

Bagsv\u00e6rd, Denmark, 12 May 2026 \u2014 This company announcement
\ndiscloses the data of the transaction(s) made in Novo Nordisk shares by the company\u2019s board members, executives and their associated
\npersons in accordance with Article 19 of Regulation No. 596\/2014 on market abuse. The company\u2019s board members, executives and their
\nassociated persons have reported the transactions to Novo Nordisk.<\/p>\n

\u00a0<\/p>\n

1<\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated
\n \u00a0<\/p>\n

a)
\n Name of the Board member\/Executive\/Associated
\n Person
\n Caroline Munk
\n Esbjerg
\n \u00a0<\/p>\n

2<\/p>\n

Reason for
\n the notification
\n \u00a0<\/p>\n

a)
\n Position\/status
\n Closely associated
\n person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)
\n \u00a0<\/p>\n

b)
\n Initial notification\/Amendment
\n Initial notification
\n \u00a0<\/p>\n

3<\/p>\n

Details of
\n the issuer
\n \u00a0<\/p>\n

a)
\n Name
\n Novo Nordisk
\n A\/S
\n \u00a0<\/p>\n

b)
\n LEI
\n 549300DAQ1CVT6CXN342
\n \u00a0<\/p>\n

4<\/p>\n

Details of
\n the transaction(s)
\n \u00a0<\/p>\n

a)
\n Description of the financial instrument,
type of instrument,
\n Shares<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0
\n Identification code
\n Novo Nordisk
\n B DK0062498333
\n \u00a0<\/p>\n

b)
\n Nature of the transaction
\n Shares received
\n as gift \u00a0
\n \u00a0<\/p>\n

c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0
\n \u00a0<\/p>\n

\u00a0
\n DKK 294.30
\n 50
\n \u00a0
\n \u00a0<\/p>\n

\u00a0
\n \u00a0
\n \u00a0
\n \u00a0
\n \u00a0<\/p>\n

d)
\n Aggregated
\n information<\/p>\n

\u00a0<\/p>\n

50
\n shares
DKK 14,715<\/p>\n

\u00a0<\/p>\n

e)
\n Date of the transaction
\n 2026-05-07
\n \u00a0<\/p>\n

f)
\n Place of the transaction
\n Outside a
\n trading venue
\n \u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

1<\/p>\n

Details of the person discharging managerial responsibilities\/person closely associated
\n \u00a0<\/p>\n

a)
\n Name of the Board member\/Executive\/Associated
\n Person
\n Sofie Munk
\n Esbjerg
\n \u00a0<\/p>\n

2<\/p>\n

Reason for
\n the notification
\n \u00a0<\/p>\n

a)
\n Position\/status
\n Closely associated
\n person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO)
\n \u00a0<\/p>\n

b)
\n Initial notification\/Amendment
\n Initial notification
\n \u00a0<\/p>\n

3<\/p>\n

Details of
\n the issuer
\n \u00a0<\/p>\n

a)
\n Name
\n Novo Nordisk
\n A\/S
\n \u00a0<\/p>\n

b)
\n LEI
\n 549300DAQ1CVT6CXN342
\n \u00a0<\/p>\n

4<\/p>\n

Details of
\n the transaction(s)
\n \u00a0<\/p>\n

a)
\n Description of the financial instrument,
type of instrument,
\n Shares<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0
\n Identification code
\n Novo Nordisk
\n B DK0062498333
\n \u00a0<\/p>\n

b)
\n Nature of the transaction
\n Shares received
\n as gift\u00a0
\n \u00a0<\/p>\n

c)
\n Price(s) and volume(s)
\n \u00a0
\n Price(s)
\n Volume(s)
\n \u00a0
\n \u00a0<\/p>\n

\u00a0
\n DKK 294.25
\n 50
\n \u00a0
\n \u00a0<\/p>\n

\u00a0
\n \u00a0
\n \u00a0
\n \u00a0
\n \u00a0<\/p>\n

d)
\n Aggregated
\n information<\/p>\n

\u00a0<\/p>\n

50
\n shares
DKK 14,712.50<\/p>\n

\u00a0<\/p>\n

e)
\n Date of the transaction
\n 2026-05-07
\n \u00a0<\/p>\n

f)
\n Place of the transaction
\n Outside a
\n trading venue
\n \u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

About Novo Nordisk<\/p>\n

Novo Nordisk is a leading global healthcare
\ncompany founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our
\nheritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and
\nultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For
\nmore information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

Contacts for further information<\/p>\n

\u00a0<\/p>\n

Media:
\n \u00a0<\/p>\n

Ambre James-Brown
\n Liz Skrbkova (US)<\/p>\n

+45 3079 9289
\n +1 609 917 0632<\/p>\n

abmo@novonordisk.com
\n lzsk@novonordisk.com<\/p>\n

\u00a0
\n \u00a0<\/p>\n

Investors:
\n \u00a0<\/p>\n

Michael Novod
\n Jacob Martin Wiborg Rode<\/p>\n

+45 3075 6050
\n +45 3075 5956<\/p>\n

nvno@novonordisk.com
\n jrde@novonordisk.com<\/p>\n

\u00a0
\n \u00a0<\/p>\n

Max Ung
\n Sina Meyer<\/p>\n

+45 3077 6414
\n +45 3079 6656<\/p>\n

mxun@novonordisk.com
\n azey@novonordisk.com<\/p>\n

\u00a0
\n \u00a0<\/p>\n

Alex Bruce
\n Christoffer Sho Togo Tullin<\/p>\n

+45 3444 2613
\n +45 3079 1471<\/p>\n

axeu@novonordisk.com
\n cftu@novonordisk.com<\/p>\n

\u00a0
\n \u00a0<\/p>\n

Mads Berner Bruun
\n Frederik Taylor Pitter<\/p>\n

+45 3075 2936
\n +1 609 613 0568<\/p>\n

mbbz@novonordisk.com
\n fptr@novonordisk.com<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

Novo Nordisk A\/S<\/p>\n

Investor Relations<\/p>\n

Novo All\u00e9 1<\/p>\n

2880 Bagsv\u00e6rd<\/p>\n

Denmark<\/p>\n

Telephone:<\/p>\n

+45 4444 8888<\/p>\n

www.novonordisk.com
CVR no: 24 25 67 90<\/p>\n

\u00a0\u00a0\u00a0Company
\n announcement No 31\/ 2026<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

SIGNATURES<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
\nduly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.<\/p>\n

\u00a0<\/p>\n

Date: May 12, 2026<\/p>\n

\u00a0<\/p>\n

NOVO NORDISK A\/S<\/p>\n

\u00a0<\/p>\n

Maziar Mike Doustdar<\/p>\n

Chief Executive Officer<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 ________________ \u00a0 FORM 6-K ________________ \u00a0 REPORT…\n","protected":false},"author":2,"featured_media":56961,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[43473,43474,31511,43472,43471,32355,272,3859],"class_list":{"0":"post-81599","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-cfo-associates","9":"tag-danish-healthcare-company","10":"tag-form-6-k","11":"tag-gifted-shares","12":"tag-insider-transactions","13":"tag-market-abuse-regulation","14":"tag-novo-nordisk","15":"tag-nvo"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116567491855632769","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/81599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=81599"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/81599\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/56961"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=81599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=81599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=81599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}